Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a relatively quiet earnings call, shifting investor focus toward the timing and framing of VESPER-3 obesity data.
Additionally, Cantor Fitzgerald suggested that incremental updates regarding the Lyme disease vaccine, mevro for prostate cancer, and sigvotatug vedotin for non-small cell lung cancer will likely be more influential than the Q4 2025 results.
Time to Go Short on Pfizer (PFE)?
In other news, on January 10, Pfizer announced positive results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab and FOLFIRI for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. The study showed a statistically significant and clinically meaningful confirmed objective response rate of 64.4% compared to 39.2% for patients receiving the standard-of-care FOLFIRI regimen. These findings suggest that the BRAFTOVI combination provides a durable response and potential flexibility in chemotherapy backbones for this aggressive cancer.
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. The company offers medicines and vaccines in various therapeutic areas.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
